联合放化疗在子宫内膜癌治疗中应用价值的Meta分析  

Application Value of Combined Radio-and Chemo-therapy for Endometrial Cancer:A Meta-analysis

作　　者：董晓燕[1] 迟宝荣[1] 杨雷[1] 刘蒙蒙[1] 单既英[1] 金凤岚[1] 范秀丽[1] 刘子玲[1] 

机构地区：[1]吉林大学第一医院肿瘤中心,吉林省长春市130021

出　　处：《中国全科医学》2011年第12期1328-1330,共3页Chinese General Practice

摘　　要：目的探讨联合放化疗对Ⅰ～Ⅲ期合并有高危因素的子宫内膜癌的总生存率、无病生存率、肿瘤特异生存率、局部复发率及远处转移率的影响。方法采用Cochrane协作网提供的Revman 4.2版软件对所纳入的随机对照试验(RCT)文献进行荟萃分析。结果共纳入文献4篇,联合放化疗组和单纯放疗组比较,5年无进展生存率及肿瘤特异生存率合并后的RR值分别为1.13[95%CI(1.02,1.25)]及1.12[95%CI(1.03,1.21)],两组间差异有统计学意义(P<0.05);5年总生存率、局部复发率及远处转移率合并后的RR值分别为1.04[95%CI(0.96,1.12)]、0.35[95%CI(0.11,1.11)]及1.01[95%CI(0.57,1.79)],两组间差异无统计学意义(P>0.05)。结论联合放化疗可显著改善Ⅰ～Ⅲ期合并有高危因素的子宫内膜癌的5年无进展生存及肿瘤特异生存,但对改善总生存及降低复发风险方面的疗效尚不确定。Objective To explore the influence of combined radio-and chemo-therapy on overall survival,progression free survival,tumor specific survival,local recurrence and distant metastasis rate of endometrial cancer at stagesⅠ~Ⅲ with high-risk factors.Methods Revman 4.2 software was used to perform meta-analysis on literatures of enrolled randomized controlled trials（RCT）.Results A total of 4 literatures were enrolled.There was significant difference in RR of 5-year progression free survival rate and tumor specific survival rate between combined radio-and chemo-therapy group [1.13,95%CI（1.02,1.25）] and simple radiotherapy group [1.12,95%CI（1.03,1.21）]（P0.05）,but there was not in RR of 5-year overall survival rate,local recurrence rate and distant metastasis rate {1.04[95%CI（0.96,1.12）],0.35[95%CI（0.11,1.11）],1.01[95%CI（0.57,1.79）],（P0.05）}.Conclusion Combined radio-and chemo-therapy can improve significantly 5-year progression free survival and tumor specific survival of endometrial cancer at stagesⅠ~Ⅲ with high-risk factors,but its efficacy in improving 5-year overall survival and reducing recurrence risk is still uncertain.

关 键 词：子宫内膜癌 放射疗法 化学疗法 META分析 

分 类 号：R711[医药卫生—妇产科学]